Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

NCT ID
NCT05569772
Registry status
Recruiting
Study type
Not specified in the registry data
Phase
Phase 3
Sponsor
Universitaire Ziekenhuizen KU Leuven

Overview

ClinicalTrials.gov lists this study as Recruiting.

Enrollment: 252 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages
Not specified in the registry data
Sex
Not specified in the registry data
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Eligible participants are women aged ≥18 years, with a history of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \<24 weeks for early GDM). Participants must have prediabetes diagnosed between 6 weeks and 12 months postpartum according to ADA criteria (FPG 5.6-6.9 mmol/L, 2-hour OGTT glucose 7.8-11.0 mmol/L and/or HbA1c 39-46 mmol/mol \[5.7-6.4%\]). Additional inclusion criteria include cessation of breastfeeding, no intention to become pregnant within the next year, use of effective contraception and no use of medication affecting glucose metabolism. Written ICF is obtained prior to any study-related procedures. Exclusion criteria include established diabetes, presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous bariatric surgery or planned surgery within two years, unable to understand and speak Dutch, French or English and current pregnant or planning to become pregnant within one year after participating in the study.

Study locations

13 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Belgium

Sample of listed locations

  • AZORG — Aalst, Belgium — Site recruitment status not specified in the registry data
  • UZA — Antwerp, Belgium — Site recruitment status not specified in the registry data
  • ZAS — Antwerp, Belgium — Site recruitment status not specified in the registry data
  • AZ St Jan Brugge — Bruges, Belgium — Site recruitment status not specified in the registry data
  • Erasme — Brussels, Belgium — Site recruitment status not specified in the registry data
  • UZ Brussel — Brussels, Belgium — Site recruitment status not specified in the registry data
  • Jan Yperman — Ieper, Belgium — Site recruitment status not specified in the registry data
  • AZ Groeninge Kortrijk — Kortrijk, Belgium — Site recruitment status not specified in the registry data
  • UZ Leuven — Leuven, Belgium — Site recruitment status not specified in the registry data
  • CHU de Liège — Liège, Belgium — Site recruitment status not specified in the registry data
  • Centre Hospitalier Mouscron — Mouscron, Belgium — Site recruitment status not specified in the registry data
  • Vitaz — Sint-Niklaas, Belgium — Site recruitment status not specified in the registry data
  • AZ Turnhout — Turnhout, Belgium — Site recruitment status not specified in the registry data

Study details

Start date
September 14, 2023
Primary completion date
March 1, 2030
First posted
October 6, 2022

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT05569772
Registry last updated
September 15, 2026
QualifiedStudies registry data refreshed
September 21, 2026

View NCT05569772 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ